ReGenX, Audentes Team Up to Develop Rare Muscle Disease Treatments

ReGenX and Audentes have decided to work together in order to develop and market new drugs to treat an X-linked disorder called myotubular myopathy. The companies will be focusing on NAV vectors, which use recombinant virus to deliver genes to human cells.
Genetic Engineering & Biotechnology News